However, its prognostic significance needs to be further confirmed in large glioma samples, and, hitherto, no studies have explored the role of LGALS3 in the glioma immune microenvironment and its correlation with key molecular markers, including isocitrate dehydrogenase 1 (IDH1), alpha-thalassemia/mental retardation X-linked (ATRX), O-6-methylguanine-DNA methyltransferase (MGMT), telomerase reverse transcriptase (TERT), and 1p19q. The gene discussed is IDH1; the disease is glioma.